Rankings
▼
Calendar
VCYT Q4 2024 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena
VCYT
Veracyte, Inc.
$3B
Q4 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$119M
+20.8% YoY
Gross Profit
$79M
66.4% margin
Operating Income
$4M
3.5% margin
Net Income
$5M
4.3% margin
EPS (Diluted)
$0.06
QoQ Revenue Growth
+2.4%
Cash Flow
Operating Cash Flow
$25M
Free Cash Flow
$20M
Stock-Based Comp.
$10M
Balance Sheet
Total Assets
$1.3B
Total Liabilities
$124M
Stockholders' Equity
$1.2B
Cash & Equivalents
$239M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$119M
$98M
+20.8%
Gross Profit
$79M
$69M
+14.4%
Operating Income
$4M
-$36M
+111.8%
Net Income
$5M
-$28M
+118.1%
Revenue Segments
Testing
$219M
94%
Biopharmaceutical And Other
$7M
3%
Product
$7M
3%
Geographic Segments
UNITED STATES
$424M
95%
Non-US
$22M
5%
← FY 2024
All Quarters
Q1 2025 →